EGFR and glioblastoma: To gain further insight into the predictive value of these biomarkers in molecular subgroups of gliomas, we analyzed the effect of EGFR amplification, PTEN deletion and MGMT promoter methylation in the response to therapy using the only group with representative samples - GBM IDH-wildtype (Fig. 4).